Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Gemtuzumab Ozogamicin (GO, MylotargTM) in Combination Therapy for Patients Over Age 60 With Previously Untreated Acute Myeloid Leukemia.

Next Previous
Trial Profile

Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Gemtuzumab Ozogamicin (GO, MylotargTM) in Combination Therapy for Patients Over Age 60 With Previously Untreated Acute Myeloid Leukemia.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 22 Aug 2012 Planned End Date changed from 1 Aug 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
  • 02 Mar 2012 Additional lead trial investigator (John M. Pagel) identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top